Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia

British Journal of Haematology

Volumn 136, Issue 4, 2007, Pages 590-596

  Bolufer, Pascual ^a   Collado, Maria ^a   Barragan, Eva ^a   Calasanz, María José ^b   Colomer, Dolors ^c   Tormo, Mar ^d   González, Marcos ^e   Brunet, Salut ^f   Batlle, Montserrat ^g   Cervera, José ^a   Sanz, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Department of Haematology   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Drug metabolising enzymes; Polymorphisms; Therapy related leukaemia; Therapy related myelodisplatic syndrome

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FOLIC ACID DERIVATIVE; GYRASE INHIBITOR; PLATINUM DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME POLYMORPHISM; EWING SARCOMA; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTOXICITY; HODGKIN DISEASE; HUMAN; INCIDENCE; INTESTINE CARCINOMA; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVARY CANCER; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; STOMACH CANCER; UTERINE CERVIX CARCINOMA; UTERINE TUBE CARCINOMA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 33846407922     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06469.x     Document Type: Article

References (40)

1. von Ahsen, N., Richter, M., Grupp, C., Ringe, B., Oellerich, M. & Armstrong, V.W. (2001) No Influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V Allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clinical Chemistry, 47, 1048-1052.
2. Allan, J.M., Wild, Ch.P., Rollinson, S., Willett, E.V., Moorman, A.V., Dovey, G.J., Roddam, P.L., Roman, E., Cartwright, R.A. & Morgan, G.J. (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukemia. Proceedings of National Academy of Sciences of the United States of America, 98, 11592-11597.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1976) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American- British Cooperative group. British Journal of Haematology, 33, 451-458.
4. Birch, J.M. (1999) Genes and cancer. Archives of Diseases of Children, 80, 1-6.
5. Blanco, J.G., Edick, M.J., Hancock, M.L., Winick, N.J., Dervieux, T., Amylon, M.D., Bash, R.O., Behm, F.G., Camitta, B.M., Pui, C.H., Raimondi, S.C. & Relling, M.V. (2002) Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics, 12, 605-611.
6. Chen, H., Sandler, D.P., Taylor, J.A., Shore, D.L., Liu, E., Bloomfield, C.D. & Bell, D.A. (1996) Increased risk for myelodisplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet, 347, 295-297.
7. Choi, J.Y., Abel, J., Neuhaus, T., Ko, Y., Harth, V., Hamajima, N., Tajima, K., Yoo, K.Y., Park, S.K., Noh, D.Y., Han, W., Choe, K.J., Ahn, S.H., Kim, S.U., Hirvonen, A. & Kang, D. (2003) Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics, 13, 67-72.
8. Collado, M., Barragán, E., Calasanz, M.J., Larrayoz, M.J., Colomer, D., Munarriz, B., Verdeguer, A., Gutierrez, A., Batlle, M., Sanz, M.A. & Bolufer, P. (2005) Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia [letter]. Leukemia Research, 29, 595-597.
9. D'Alo, F., Voso, M.T., Guidi, F., Massini, G., Scardocci, A., Sica, S., Pagano, L., Hohaus, S. & Leone, G. (2004) Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica, 89, 664-670.
10. Donaldson, S.S. & Hancock, S.L. (1997) Second cancers after Hodgkin's disease in childhood. New England Journal of Medicine 334, 792-793.
11. Engbersen, A.M., Franken, D.G., Boers, G.H., Stevens, E.M., Trijbels, F.J. & Blom, H.J. (1995) Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. American Journal of Human Genetics, 56, 142-150.
12. Felix, C.A., Walker, A.H., Lange, B.J., Williams, T.M., Winicki, N.J., Cheung, N.K.V., Lovett, B.D., Nowell, P.C., Blair, I.A. & Rebbeck, T.R. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proceedings of National Academy of Science of the United States of America, 95, 13176-13181.
13. Flannery, J.T., Boice, J.D., Devesa, S.S., Kleinerman, R.A., Curtis, R.E. & Fraumeni, J.F. (1985) Cancer registration in Connecticut and the study of multiple primary cancers, 1935-82. National Cancer Institute Monograph, 68, 13-24.
14. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, Ch., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., Goldstone, A & On behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood, 92, 2322-2333.
15. Harth, V., Donat, S., Ko, Y., Abel, J., Vetter, H. & Bruning, T. (2000) NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Archives of Toxicology, 73, 528-531.
16. Harth, V., Bruning, T., Abel, J., Koch, B., Berg, I., Sachinidis, A., Bolt, H.M., Vetter, H. & Ko, Y. (2001) Real-time genotyping of cytochrome P4501A1 A4889G and T6235C polymorphisms. Molecular and cellular probes, 15, 93-97.
17. Hayashi, S., Watanabe, J., Nakachi, K. & Kawajiri, K. (1991) Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. Journal of Biochemistry (Tokyo), 110, 559-565.
18. Ingelman-Sundberg, M. (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutation Research, 482, 11-19.
19. Kawajiri, K., Nakachi, K., Imai, K., Yoshü, A., Shinada, N. & Watanabe, J. (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Letters, 263, 131-133.
20. Kelly, K.M. & Perentesis, J.P. (2002) Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Annals of Oncology, 13(Suppl. 1), 34-39.
21. Kollmannsberger, C., Hartmann, J.T., Kanz, L. & Bokemeyer, C. (1998) Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.(Review). Journal of Cancer Research and Clinical Oncology, 124, 207-214.
22. Krajinovic, M. (2005) Further insight into the role of NQO1 in childhood leukemia. Haematologica, 90, 1445.
23. Krajinovic, M., Lamothe, S., Labuda, D., Lemieux-Blanchard, M., Théorêt, Y., Moghrabi, A. & Sinnet, D. (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood, 103, 252-257.
24. Larson, R.A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C., Le Beau, M.M. & Smith, M.T. (1999) Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-807.
25. Levine, E.G. & Bloomfield, C.D. (1992) Leukemias and myielodisplastic syndromes secondary to drug, radiation and enviromental exposure. Seminars in Oncology, 19, 47-84.
26. Levy-Lahad, E., Lahad, A., Eisenberg, S., Dagan, E., Paperna, T., Kasinetz, L., Catane, R., Kaufman, B., Beller, U., Renbaum, P. & Gershoni-Baruch, R. (2001). A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proceedings of National Academy of Science of the United States of America, 6, 3232-3236.
27. Marsh, S., Ameyaw, M.M., Githang'a, J., Indalo, A., Ofori-Adjei, D. & McLeod, H.L. (2000) Novel thymidylate synthase enhancer region alleles in African populations. Human Mutation, 16, 528.
28. Mitelman, F, ed. ISCN 1995. (1995) An International System for Human Cytogenetic Nomenclature 1995. S Karger, Basel, Switzerland.
29. Moran, J.L., Siegel, D. & Ross, D. (1999) A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H: quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proceedings of National Academy of Science of the United States of America, 96, 8150-8155.
30. Naoe, T., Takeyama, K., Yokozawa, T., Kiyoi, H., Seto, M., Uike, N., Ino, T., Utsunomiya, A., Maruta, A., Jin-nai, I., Kamada, N., Kubota, Y., Nakamura, H., Shimazaki, C., Horiike, S., Kodera, Y., Saito, H., Ueda, R., Wiemels, J. & Ohno, R. (2000) Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clinical Cancer Research, 6, 4091-4095.
31. Perentesis, J.P. (2001) Genetic predisposition and treatment-related leukemia. Medical and Pediatric Oncology, 36, 541-548.
32. Radjendirane, V., Joseph, P., Lee, Y., Kimura, S., Klein-Szantoi, A.J.P., Gonzalez, F.J. & Jaiswal, A.K. (1998) Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. Journal of Biological Chemistry, 273, 7382-7389.
33. Rocha, J.C., Cheng, C., Liu, W., Kishi, S., Das, S., Cook, E.H., Sandlund, J.T., Rubnitz, J., Ribeiro, R., Campana, D., Pui, C.H., Evans, W.E. & Relling, M.V. (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 105, 4752-4758.
34. Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Fujii, H., Kashima, K. & Taniwaki, M. (1999) Genotype of glutathione S-transferase and other configurations in myelodysplasia. Leukemia Research, 23, 975-981.
35. Seidegard, J., Vorachek, W.R., Pero, R.W., Pearson, W.R. (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are because of a gene deletion. Proceedings of National Academy of Science of the United States of the America, 85, 7293-7297.
36. Skibola, C.F., Smith, M.T., Hubbard, A., Shane, B., Roberts, A.C., Law, G.R., Rollinson, S., Roman, E., Cartwright, R.A. & Morgan, G.J. (2002) Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood, 99, 3786-3791.
37. Traver, R.D., Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H., Danenberg, P.V., Ross, D. & Gibson, N.W. (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Research, 52, 797-802.
38. Villafranca, E., Okruzhnov, Y., Dominguez, M.A., Garcia-Foncillas, J., Azinovic, I., Martinez, E., Illarramendi, J.J., Arias, F., Martinez, M.R., Salgado, E., Angeletti, S. & Brugarolas, A. (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. Journal of Clinical Oncology, 19, 1779-1786.
39. Voso, M.T., D'Alò, F., Gumiero, D., Guidi, F., Hohaus, S. & Leone, G. (2005) The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica, 90, 982-984.
40. Wolden, S.L., Lamborn, K.L., Clearly, S.F., Tate, D.J. & Donalson, S. (1998) Second cancers following pediatric Hodgkin's disease. Journal of Clinical Oncology, 16, 536-544.